Definitive Contract HDTRA122C0006
Award Date
12/14/21
Potential Completion Date
6/13/25
Potential Value
$4.9M
Federal Agency
Defense Threat Reduction Agency
Awardee
The General Hospital Corporation
Ultimate Awardee
Partners Healthcare System Incorporated
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AC33 - National Defense R&D Services; Defense-Related Activities; Experimental Development
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Boston, MA 02114, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $4,440,253.00 definitive federal contract awarded by the Defense Threat Reduction Agency (DTRA) to the University of Texas Medical Branch at Galveston (UTMB) for "QUANTITATIVE DOSE EBOLA" research. The contract has no set-aside designation. UTMB, a state government entity and educational institution, has extensive experience supporting federal agencies in infectious disease research, medical countermeasure development, and biosafety training. The contract provides funding for...
This is a $5,222,170 cost-no-fee definitive contract awarded by the Defense Threat Reduction Agency (DTRA) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The contract is for a base period with a completion date of June 19, 2020 and does not have a set-aside designation. The objective of the contract is to develop a T cell-based vaccine for Q fever (Coxiella burnetii). MGH is the prime contractor, with multiple subcontractors including the...
This is a $2,594,319.91 federal contract awarded by the Defense Threat Reduction Agency (DTRA) to Microbiotix, Inc., a clinical-stage biopharmaceutical company. The contract is for the development of novel small molecule therapeutics to treat infections by Ebola and Marburg viruses. The contract is a Definitive Contract with a Cost Plus Fixed Fee pricing type, with a period of performance ending on December 14, 2020. Microbiotix has subcontracted with the Albert Einstein College of Medicine...
This contract was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $43,075,091.00 cost-plus-fixed-fee contract provides research, development, and production services to support studies and operations related to the Ebola virus and other emerging and re-emerging infectious diseases. Leidos Biomedical Research has served as a prime contractor and...
This is a federal contract awarded by the Defense Threat Reduction Agency (DTRA), a defense agency, to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in the development of antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract, valued at $6,173,324.00, is for research and development services during the base period, with a period of performance ending on August 31, 2017. The contract is a Cost Plus Fixed Fee Definitive...
This $2,306,148 federal contract was awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Battelle Memorial Institute to support an efficacy study of a monoclonal antibody (MAb) therapeutic against the Ebola virus (EBOV) lethal challenge in rhesus macaques. The contract is a Delivery Order issued under Battelle's BARDA Biological Animal Model Development 2017-2022 Indefinite Delivery/Indefinite Quantity (IDIQ)...
This federal contract award, with ID HDTRA116C0025, was issued by the Defense Threat Reduction Agency (DTRA) to The Trustees of Princeton University, a private non-profit research university, for the development of an "Ultrasensitive Rapid Ebola Virus Antigen Diagnostic Assay" during the base period. The $5,567,820.56 definitive contract has a cost-no-fee pricing type and a completion date of October 1, 2019. It did not have a set-aside designation. The prime contractor, Princeton...
This is a delivery order awarded under the Homeland Defense and Security Technical Area Tasks (HD TATs) IDIQ contract, issued by the U.S. Air Force Materiel Command. The $5,256,015.00 contract was awarded to Battelle Memorial Institute, a non-profit research and development organization, to provide Ebola diagnostics, field analytics, and sequencing support for the Joint Product Manager Medical Countermeasure Systems. Luminex Corporation, a manufacturer of biological testing technologies, was...
<p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $12.2 million delivery order contract to Leidos Biomedical Research Inc. to support research, development, and production efforts related to Ebola bispecific antibody development. As the prime contractor, Leidos Biomedical Research will perform work at its place of performance in Fort Detrick, Maryland under a cost plus fixed fee contract running from September 2022 through July 2028.</p>
This federal contract award, valued at $73,343,960.25, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Leidos Biomedical Research Inc. The contract supports research on the Ebola virus and other infectious diseases. The scope of work includes but is not limited to strategic and operational planning, infrastructure operations and maintenance, logistics and procurement management, clinical research protocol...